HeyJaredFred Imbert
- Indexed articles, last 90 days
- 84
- Latest publication
- Oct 1, 2026
- Outlet visibility, for CNBC
- Top 5K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
October by the numbers: A typically strong month with a scary reputation (opens the original)
Read excerpt
September lived up to its choppy reputation, with investors closing out the month with mixed performances. The S & P 500 and Dow Jones Industrial Average posted monthly declines, while the Nasdaq Composite rose for a second month. It was the third monthly pullback in four months for the S & P 500, while the Dow broke a five-month-long advance. Equities were volatile throughout September, with traders recalibrating monetary policy expectations seemingly day by day, as inflation showed little sign
Inflation moves in the right direction, but markets are still not out of the woods (opens the original)
Read excerpt
Wall Street got some much-needed inflation data on Wednesday. The personal consumption expenditures price index rose 3.4% year over year in August, well below a Dow Jones forecast of 3.7%. Excluding food and energy, PCE increased by 3% year over year , also less than anticipated. Those numbers gave equities a boost in early trading while moving Treasury yields off of multiyear highs. It also moved odds of an October rate hike to 35% from around 50% on Tuesday, per the CME Group's FedWatch tool.
Moderna has been on a tear since mid-August. Citi now sees it plunging 60% (opens the original)
Read excerpt
It's time for Moderna shareholders to bail on the stock, according to Citi. Analyst Geoff Meacham downgraded the biotech name to sell. He raised his price target to $80 from $60, though that implies 60% downside from Tuesday's close. Moderna has been on a tear since Aug. 19 , when the company announced positive late-stage trial results for an experimental personalized cancer vaccine known as intismeran autogene. The drug, combined with Merck's Keytruda, met goals in more than 1,100 patients with
Stocks making the biggest moves midday: Carnival, Fair Isaac, Bloom Energy, Iovance Biotherapeutics & more (opens the original)
Read excerpt
Here are some of the companies making headlines in midday trading. Carnival â Carnival's stock rose 12% after the cruise operator reported third-quarter earnings ahead of Wall Street estimates before the market open. Management reported that bookings were strong despite the macro challenges facing consumers, and noted the 2027 calendar year was booked at record occupancy while 2028 occupancy and prices were also higher year over year. Shares of Royal Caribbean and Norwegian Cruise Line advance
Stocks making the biggest moves premarket: Fair Isaac, SpaceX, AMD & more (opens the original)
Read excerpt
Check out the companies making the biggest moves premarket: Fair Isaac â Shares plunged 18% after Federal Housing Finance Agency director Bill Pulte introduced changes to mortgage pricing. "We are Simplifying Mortgage Pricing following feedback from lenders and consumers. Instead of two separate pricing grids, which makes zero sense, Fannie and Freddie are hereby moving to ONE PRICING GRID with VantageScore joining the existing FICO Classic pricing grid," Pulte said in a post on X. AMD â The
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5K sites
For CNBC, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.